Trial Profile
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Selinexor (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Eribulin; Etoposide; Fluorouracil; Folinic acid; Irinotecan; Olaparib; Oxaliplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Topotecan
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Triple negative breast cancer; Uveal melanoma
- Focus Adverse reactions
- 15 Jun 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 15 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 15 Jun 2023 Status changed from recruiting to active, no longer recruiting.